Medicine and Dentistry
Patient
100%
Cohort Analysis
35%
Lymphoma
29%
Non-Hodgkin Lymphoma
27%
Hodgkin's Lymphoma
25%
Survival
25%
Therapeutic Procedure
25%
Diffuse Large B-Cell Lymphoma
22%
Spontaneous Remission
22%
Adult
18%
Drug Megadose
18%
Acute Myeloid Leukemia
16%
Reproductive Medicine
16%
Methotrexate
16%
Prophylaxis
16%
B-Cell Lymphoma
16%
Diagnosis
16%
Relapse
14%
Overall Survival
13%
Childbirth
13%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
13%
Inpatient
13%
Combination Therapy
13%
Psychoactive Drug
13%
Analysis
12%
Age
11%
Assisted Reproductive Technology
11%
Anxiety
10%
Cancer
9%
Male
9%
Mental Health
9%
Prognosis
9%
BEACOPP
9%
Female
9%
Central Nervous System
8%
Burkitt's Lymphoma
8%
Systematic Review
8%
Health Care
8%
Osteoporosis
8%
Steroid
8%
Diabetes
8%
Clinical Trial
8%
Drug Use
8%
Classical Hodgkin Lymphoma
8%
ABVD
8%
Somatics
8%
Loss of Function Mutation
8%
Hazard Ratio
7%
Diabetes Mellitus
7%
Population
6%
Pharmacology, Toxicology and Pharmaceutical Science
Cohort Study
26%
Psychotropic Agent
21%
Nonhodgkin Lymphoma
20%
Acute Myeloid Leukemia
16%
Methotrexate
16%
Lymphoma
15%
Depression
11%
Remission
9%
Prognosis
9%
Incidence
8%
Hodgkin Disease
8%
Diffuse Large B Cell Lymphoma
8%
Myeloproliferative Neoplasm
8%
Myelodysplastic Syndrome
8%
Diabetes Mellitus
8%
Steroids
8%
Case-Control Study
8%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
8%
Classical Hodgkin Lymphoma
8%
B Cell Lymphoma
8%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
5%
Statin (Protein)
5%
